BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was the recipient of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 15,750,000 shares, an increase of 13.0% from the September 30th total of 13,940,000 shares. Based on an average daily volume of 1,440,000 shares, the days-to-cover ratio is currently 10.9 days. Approximately 14.5% of the shares of the company are short sold.
BioCryst Pharmaceuticals stock traded up $0.16 during midday trading on Friday, reaching $1.75. The company’s stock had a trading volume of 5,061,300 shares, compared to its average volume of 1,526,023. The firm has a market capitalization of $176.70 million, a PE ratio of -1.79 and a beta of 1.86. The stock’s 50 day simple moving average is $2.38 and its 200 day simple moving average is $3.53. BioCryst Pharmaceuticals has a fifty-two week low of $1.38 and a fifty-two week high of $9.95. The company has a debt-to-equity ratio of 2.38, a quick ratio of 1.43 and a current ratio of 0.96.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.03). The business had revenue of $1.78 million during the quarter, compared to analysts’ expectations of $4.54 million. BioCryst Pharmaceuticals had a negative net margin of 1,129.38% and a negative return on equity of 2,511.40%. Equities analysts predict that BioCryst Pharmaceuticals will post -1.25 earnings per share for the current year.
Institutional investors and hedge funds have recently bought and sold shares of the business. Bank of Montreal Can grew its holdings in BioCryst Pharmaceuticals by 921.9% in the 2nd quarter. Bank of Montreal Can now owns 10,219 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 9,219 shares during the period. Quantamental Technologies LLC purchased a new stake in BioCryst Pharmaceuticals in the 2nd quarter valued at about $43,000. Jane Street Group LLC purchased a new stake in BioCryst Pharmaceuticals in the 2nd quarter valued at about $69,000. Cubist Systematic Strategies LLC grew its holdings in BioCryst Pharmaceuticals by 143.6% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 27,016 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 15,924 shares during the period. Finally, Quantitative Systematic Strategies LLC grew its holdings in BioCryst Pharmaceuticals by 297.3% in the 2nd quarter. Quantitative Systematic Strategies LLC now owns 43,590 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 32,618 shares during the period. Institutional investors own 90.62% of the company’s stock.
Several brokerages recently weighed in on BCRX. Zacks Investment Research downgraded BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 8th. ValuEngine downgraded BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, November 4th. Needham & Company LLC reaffirmed a “hold” rating on shares of BioCryst Pharmaceuticals in a report on Wednesday, November 6th. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price target on shares of BioCryst Pharmaceuticals in a report on Thursday, October 31st. Finally, Bank of America raised BioCryst Pharmaceuticals from a “neutral” rating to a “buy” rating and decreased their price target for the stock from $5.00 to $4.00 in a report on Friday. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $8.94.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.
See Also: Inverted Yield Curve
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.